A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials.

ABSTRACT: The pathogenic processes driving Alzheimer's disease (AD) are complex. An incomplete understanding of underlying disease mechanisms has presented insurmountable obstacles for developing effective disease-modifying therapies. Advanced chronological age is the greatest risk factor for developing AD. Intervening on biological aging may alter disease progression and represents a novel, complementary approach to current strategies. Toward this end, cellular senescence has emerged as a promising target. This complex stress response harbors damaged cells in a cell cycle arrested, apoptosis-resistant cell state. Senescent cells accumulate with age where they notoriously secrete molecules that contribute to chronic tissue dysfunction and disease. Thus, benefits of cell survival in a senescent fate

SUBMITTER: Gonzales MM 

PROVIDER: S-EPMC9059898 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature